Top 10 Cancer Drug Companies of 2025
The cancer drug market has experienced profound changes in recent years, marked by increased competition, shifting market shares, and the emergence of new players. While Merck, Roche and Bristol-Myers Squibb (BMS, with Celgene), and Merck remain influential, the landscape in 2025 will be far more dynamic and fragmented than before. This increased competition is fueled by the success of blockbuster drugs like Keytruda (Merck), Tagrisso (AstraZeneca), and Ibrance (Pfizer), as well as the rapid adoption of immunotherapies and targeted treatments ( Verified Market Reports ). And it won’t just be the heavy hitters clawing for a piece of the pie. That number is set to nearly double by 2024—swelling to 39.7%—thanks to big recent approvals for companies including Gilead Sciences, Eli Lilly, Tesaro, Clovis and more. This democratization of the market reflects both the rising number of new cancer cases globally and the surge in research and development, particularly in targeted therapies and per...